Ziqi Xiong, Zhenxue Li, Zhao Guan, Sen Zhou, Yiming Zhao, Ming Zhao, Xiancan Ma, Yiming Gao, Zhonghui Zhang, Pingzhang Wang, Chen Liu
{"title":"Distinct Activation and Functional Features of CD307c<sup>+</sup> T Lymphocytes in Peripheral Blood as Diagnostic and Prognostic Markers in Breast Cancer.","authors":"Ziqi Xiong, Zhenxue Li, Zhao Guan, Sen Zhou, Yiming Zhao, Ming Zhao, Xiancan Ma, Yiming Gao, Zhonghui Zhang, Pingzhang Wang, Chen Liu","doi":"10.1111/imm.13960","DOIUrl":null,"url":null,"abstract":"<p><p>This study aims to investigate the expression and role of CD307c in the breast cancer (BC) microenvironment, T lymphocytes of peripheral blood, particularly in BC patients at various stages, and assess its potential as a clinical diagnostic biomarker. Bioinformatics analysis was performed to investigate CD307c expression. As experimental validation, a total of 54 BC patients and 44 healthy controls (HCs) were enrolled. Flow cytometry was used to analyse CD307c expression in CD4<sup>+</sup> and CD8<sup>+</sup> T cells, alongside markers of T cell activation and function, such as PD-1, Ki-67, CD25, CD62L, GZMB and GZMK. Ex vivo T cell stimulation with anti-CD3 and anti-CD28 was performed to assess CD307c expression after activation. Statistical analyses, including receiver operating characteristic (ROC) curve analysis, were used to evaluate the diagnostic value of CD307c<sup>+</sup> T cell subsets. Bioinformatics analysis revealed that CD307c was significantly upregulated in BC tissues compared to adjacent normal tissues, and that CD307c was mainly expressed in lymphocytes, such as B cells, T<sub>reg</sub>s, CD8<sup>+</sup> T cells and NKs in the tumour microenvironment. In peripheral blood, CD307c expression was significantly higher in CD4<sup>+</sup> T cells compared to CD8<sup>+</sup> T cells. CD307c<sup>+</sup> T cells exhibited elevated levels of Ki-67, PD-1, CD25 and CD62L, indicating increased activation and potential for immune exhaustion. Additionally, CD307c<sup>+</sup> CD8<sup>+</sup> T cells showed higher expression of granzyme B (GZMB) and granzyme K (GZMK), markers of cytotoxicity. In BC patients, CD307c expression was significantly higher in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells compared to HCs, and the proportion of CD307c<sup>+</sup> cells varied across cancer stages. CD307c expression in T lymphocytes is elevated in early-stage BC. CD307c<sup>+</sup> T cells show enhanced activation, suggesting its potential role as a useful biomarker for early BC diagnosis and a potential therapeutic target.</p>","PeriodicalId":13508,"journal":{"name":"Immunology","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imm.13960","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study aims to investigate the expression and role of CD307c in the breast cancer (BC) microenvironment, T lymphocytes of peripheral blood, particularly in BC patients at various stages, and assess its potential as a clinical diagnostic biomarker. Bioinformatics analysis was performed to investigate CD307c expression. As experimental validation, a total of 54 BC patients and 44 healthy controls (HCs) were enrolled. Flow cytometry was used to analyse CD307c expression in CD4+ and CD8+ T cells, alongside markers of T cell activation and function, such as PD-1, Ki-67, CD25, CD62L, GZMB and GZMK. Ex vivo T cell stimulation with anti-CD3 and anti-CD28 was performed to assess CD307c expression after activation. Statistical analyses, including receiver operating characteristic (ROC) curve analysis, were used to evaluate the diagnostic value of CD307c+ T cell subsets. Bioinformatics analysis revealed that CD307c was significantly upregulated in BC tissues compared to adjacent normal tissues, and that CD307c was mainly expressed in lymphocytes, such as B cells, Tregs, CD8+ T cells and NKs in the tumour microenvironment. In peripheral blood, CD307c expression was significantly higher in CD4+ T cells compared to CD8+ T cells. CD307c+ T cells exhibited elevated levels of Ki-67, PD-1, CD25 and CD62L, indicating increased activation and potential for immune exhaustion. Additionally, CD307c+ CD8+ T cells showed higher expression of granzyme B (GZMB) and granzyme K (GZMK), markers of cytotoxicity. In BC patients, CD307c expression was significantly higher in both CD4+ and CD8+ T cells compared to HCs, and the proportion of CD307c+ cells varied across cancer stages. CD307c expression in T lymphocytes is elevated in early-stage BC. CD307c+ T cells show enhanced activation, suggesting its potential role as a useful biomarker for early BC diagnosis and a potential therapeutic target.
期刊介绍:
Immunology is one of the longest-established immunology journals and is recognised as one of the leading journals in its field. We have global representation in authors, editors and reviewers.
Immunology publishes papers describing original findings in all areas of cellular and molecular immunology. High-quality original articles describing mechanistic insights into fundamental aspects of the immune system are welcome. Topics of interest to the journal include: immune cell development, cancer immunology, systems immunology/omics and informatics, inflammation, immunometabolism, immunology of infection, microbiota and immunity, mucosal immunology, and neuroimmunology.
The journal also publishes commissioned review articles on subjects of topical interest to immunologists, and commissions in-depth review series: themed sets of review articles which take a 360° view of select topics at the heart of immunological research.